Atopic Dermatitis

Long-Term Laboratory Trends in Patients with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib: 140-Week Results from Measure Up 1 and 2 David G Cotter, Mona Shahriari, Diego Ruiz Dasilva, Erik Domingues, Shanthi Narla, Mark G Kirchhof, Rachel Goldberg, Meerat Oza, Deanne Dilley, Ayman Grada, Alan D Irvine < PREVIOUS POSTER NEXT POSTER > POSTER 13

Asthma Control in Patients with Moderate-To-Severe Atopic Dermatitis and Comorbid Asthma Receiving Lebrikizumab in a Real-World Setting: Interim Data from the AD-LIFE Non-Interventional Study Roland Buhl, Andreas Wollenberg, Thomas Bieber, Ralf Gutzmer, Afra Kempf, Sebastian Diemert, Laura Susok, Diamant Thaçi, Bob Geng, Felix Lauffer < PREVIOUS POSTER NEXT POSTER > POSTER 14

Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis Jonathan Silverberg, Vivian Laquer, Peter Lio, Kim Papp, Alan Irvine, Andrew Blauvelt, Hany Elmaraghy, Louise DeLuca-Carter, Heidi Crane, Gaia Gallo, Evangeline Pierce, Yuxin Ding7 Amy S. Paller < PREVIOUS POSTER NEXT POSTER > POSTER 15

Lebrikizumab Provides Clinically Meaningful Response in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: ADhope1 Study Primary Results Diamant Thaçi, Alan Irvine, Christian Vestergaard, Christine Bangert, Jan Gutermuth, Helena Agell, Júlia Valls Bancells, Victor Sapena, Ruth Coll, Marjolein de Bruin-Weller < PREVIOUS POSTER NEXT POSTER > POSTER 16

Real-World Effectiveness of Lebrikizumab in Atopic Dermatitis Patients at 6 Months: Results from the PPD™ CorEvitas™ AD Registry in the United States and Canada Eric L. Simpson, Vimal H. Prajapati, William McCann, Evangeline Pierce, Alvin Li, Chien-Wen J. Choi, Bryce J. Wiley, Zach Dawson, Elsa Inman, Kayla Callahan, Jonathan I. Silverberg < PREVIOUS POSTER NEXT POSTER > POSTER 17